The startup develops polygenic disease screening tests and sequencing-based assays for chromosomal aneuploidies to enhance health outcomes in in vitro fertilization (IVF) patients. Their technology enables the identification of genetic risks for conditions such as type 1 diabetes and ovarian cancer, helping to minimize potential embryo health issues.
Funding
$18.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In vitro fertilization (IVF) patients face the risk of miscarriage and genetic diseases in their embryos, which can reduce the success rate of fertility treatments. Conventional preimplantation genetic testing (PGT) methods may lack the accuracy needed to identify the healthiest embryos for transfer. This can lead to lower pregnancy rates and increased emotional and financial burden for prospective parents.
Solution
LifeView PGT offers advanced genetic screening for IVF embryos, providing more data per embryo than conventional PGT methods. The platform utilizes SNP array technology to screen for aneuploidy, monogenic disorders, and polygenic conditions. LifeView's Embryo Health Score assesses the risk of polygenic diseases such as diabetes, cancer, schizophrenia, and heart disease, enabling clinicians and patients to compare disease risks among embryos and prioritize the healthiest for transfer.
Target Audience
The primary target audience includes IVF patients and fertility clinics seeking advanced genetic screening to improve pregnancy success rates and reduce the risk of miscarriage and genetic diseases.
Features
- PGT-A screening for aneuploidy to select embryos with the correct number of chromosomes
- PGT-A+ to determine if chromosome abnormalities originated from the egg or sperm
- PGT-M for individuals with a higher chance of passing on monogenic disorders
- Embryo Health Score test to evaluate genetic variants associated with polygenic conditions
- PGT-SR for individuals who are carriers of balanced chromosome rearrangements
- M2 screening of biological parents for a gene associated with increased miscarriage risk
- High-throughput SNP array technology for comprehensive genetic analysis
- Identification of genetic risks for a range of conditions, including diabetes, cancer, and heart disease